Drug Mechanism Clinical Trial
Official title:
Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Continuous Renal Replacement Therapy
NCT number | NCT02458261 |
Other study ID # | 2014-6119 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 2015 |
Est. completion date | February 2019 |
Verified date | April 2019 |
Source | University of Cincinnati |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This prospective, multi-center study aims to determine the pharmacokinetics and pharmacodynamics of extended-infusion cefepime in continuous renal replacement therapy (CRRT).
Status | Completed |
Enrollment | 10 |
Est. completion date | February 2019 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age = 18 years - Admission to medical intensive care unit (MICU), surgical intensive care unit (SICU), neuroscience intensive care unit (NSICU), or cardiovascular intensive care unit (CVICU), at the University of Cincinnati Medical Center, or the mixed ICU at West Chester Hospital - Patients receiving continuous venovenous hemofiltration or continuous venovenous hemodialysis - Receiving empiric or definitive cefepime 2 g IV every 8 hours with a four-hour infusion Exclusion Criteria: - Prisoners - Pregnant women - Patients with cystic fibrosis - Burns patients - 24-hour urine output > 400 mL or unknown |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Cincinnati | Children's Hospital Medical Center, Cincinnati |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite pharmacokinetic and pharmacodynamic profile of extended-infusion cefepime in CRRT | Each patient will have samples collected on both the first dose and another dose at presumed steady state (dose four, five, or six) to determine the pharmacokinetic and pharmacodynamic profile of extended-infusion cefepime in CRRT. Pharmacokinetic outcomes calculated include half life, volume of distribution, and area under the plasma concentration versus time curve. Sieving and saturation coefficients will also be calculated as appropriate. Time above the minimum inhibitory concentration will be the primary pharmacodynamic outcome studied. | up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04659343 -
TDM for Optimized Outcome in Patients With mRCC.
|
||
Recruiting |
NCT01565759 -
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects
|
Phase 1 | |
Completed |
NCT06431984 -
Pharmacology Space Kit (PSK) - Dried Blood Spot for Caffeine Pharmacokinetics Under Microgravity Conditions
|
N/A | |
Completed |
NCT01963130 -
Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study
|
N/A | |
Completed |
NCT04690673 -
Detection of Paracetamol Concentration in Blood-, Saline- and Urine Samples - a Validation Study for a Novel Technique
|
N/A | |
Recruiting |
NCT05212389 -
The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling
|
N/A |